ASML Holding NV Soars 3.14% on UBS Upgrade

Generated by AI AgentAinvest Pre-Market Radar
Friday, Sep 5, 2025 8:43 am ET1min read
Aime RobotAime Summary

- ASML's stock rose 3.14% after UBS upgraded it to 'Buy' with a €750 price target, citing 20% EPS CAGR potential through 2030.

- Analysts highlight 2027 TSMC A14 node production and High NA tech adoption as key growth drivers for ASML's lithography demand.

- The company maintained 15% YoY growth targets despite mixed Q2 results, supported by €5.5B in bookings and narrowed €30-35B sales guidance.

- UBS' optimism stems from ASML's 26.4% revenue growth, 52.5% gross margin, and strategic focus on premium EUV models and upgrade revenue.

On September 5, 2025,

Holding's stock surged by 3.14% in pre-market trading, reflecting a strong bullish sentiment among investors.

UBS has upgraded

NV to a 'Buy' rating, raising its price target to €750 from €660. This move is driven by the bank's optimism about ASML's potential as a "quality compounder," with expectations of a 20% EPS CAGR from 2026 to 2030. The upgrade is supported by ASML's impressive 26.4% revenue growth and a 52.5% gross margin over the past year.

Analysts have highlighted several key growth drivers for ASML, including the anticipated 2027

from TSMC’s A14 node production and the adoption of High NA technology. These factors are expected to drive significant demand for ASML's advanced lithography solutions. Additionally, ASML's strategic shift towards higher-priced EUV models and revenue from installed base upgrades are seen as positive catalysts for future growth.

Despite mixed Q2 results, ASML has reaffirmed its 2025 sales targets, maintaining a 15% year-over-year growth outlook. This commitment to long-term targets has reinforced investor confidence in ASML's leadership position in the advanced lithography market. The company's operational resilience is further underscored by recent Q2 bookings of €5.5 billion and narrowed sales guidance to €30-35 billion.

Comments



Add a public comment...
No comments

No comments yet